See more : Automobile Corporation of Goa Limited (ACGL.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Insmed Incorporated (INSM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Insmed Incorporated, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Dr. Hönle AG (HNL.DE) Income Statement Analysis – Financial Results
- Turtle Beach Corporation (HEAR) Income Statement Analysis – Financial Results
- Sports Concepts, Inc. (SCPT) Income Statement Analysis – Financial Results
- NB Private Equity Partners Limited (NBPVF) Income Statement Analysis – Financial Results
- Brockhaus Technologies AG (BKHT.DE) Income Statement Analysis – Financial Results
Insmed Incorporated (INSM)
About Insmed Incorporated
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 305.21M | 245.36M | 188.46M | 164.41M | 136.47M | 9.84M | 0.00 | 0.00 | 0.00 | 11.50M | 11.50M | 0.00 | 4.42M | 6.92M | 10.37M | 11.70M | 7.53M | 991.00K | 131.00K | 137.00K | 150.00K | 1.96M | 296.00K | 60.00K | 663.16K |
| Cost of Revenue | 65.57M | 55.13M | 44.15M | 39.87M | 24.21M | 2.42M | 2.90M | 2.44M | 1.98M | 33.53M | 29.64M | 21.37M | 0.00 | 0.00 | 0.00 | 0.00 | 576.00K | 1.49M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -86.57K |
| Gross Profit | 239.64M | 190.23M | 144.31M | 124.54M | 112.26M | 7.41M | -2.90M | -2.44M | -1.98M | -22.03M | -18.14M | -21.37M | 4.42M | 6.92M | 10.37M | 11.70M | 6.95M | -499.00K | 131.00K | 137.00K | 150.00K | 1.96M | 296.00K | 60.00K | 749.74K |
| Gross Profit Ratio | 78.52% | 77.53% | 76.57% | 75.75% | 82.26% | 75.36% | 0.00% | 0.00% | 0.00% | -191.61% | -157.77% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 92.35% | -50.35% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 113.05% |
| Research & Development | 571.01M | 397.52M | 272.74M | 181.16M | 131.71M | 145.28M | 109.75M | 122.72M | 74.28M | 56.29M | 44.28M | 29.78M | 27.92M | 4.76M | 9.21M | 21.05M | 18.94M | 21.09M | 21.84M | 23.32M | 7.14M | 18.08M | 35.51M | 21.61M | 6.35M |
| General & Administrative | 344.50M | 244.98M | 234.27M | 203.61M | 210.80M | 168.22M | 79.17M | 50.68M | 43.22M | 31.07M | 22.24M | 12.66M | 12.23M | 10.26M | 0.00 | 0.00 | 0.00 | 0.00 | 5.73M | 2.98M | 3.48M | 2.98M | 4.98M | 9.55M | 0.00 |
| Selling & Marketing | 0.00 | 20.80M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.26M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 344.50M | 265.78M | 234.27M | 203.61M | 210.80M | 168.22M | 79.17M | 50.68M | 43.22M | 31.07M | 22.24M | 12.66M | 12.23M | 10.26M | 9.84M | 5.06M | 8.46M | 25.68M | 5.73M | 4.24M | 3.48M | 2.98M | 4.98M | 9.55M | 2.44M |
| Other Expenses | 33.75M | 5.05M | 5.05M | 5.00M | 4.99M | 602.00K | 300.00K | 119.00K | -33.00K | 141.00K | -33.00K | 0.00 | 12.23M | 10.26M | 9.84M | 5.06M | 8.46M | 32.79M | 5.73M | 4.24M | 3.60M | 18.37M | 95.00K | 0.00 | 2.53M |
| Operating Expenses | 949.26M | 668.36M | 512.07M | 389.77M | 347.50M | 314.75M | 188.92M | 173.40M | 117.49M | 87.37M | 66.52M | 42.44M | 40.15M | 15.01M | 19.05M | 26.11M | 27.39M | 53.87M | 27.57M | 27.56M | 10.74M | 36.45M | 40.48M | 31.16M | 8.88M |
| Cost & Expenses | 1.01B | 723.48M | 556.22M | 429.65M | 371.71M | 317.17M | 188.92M | 173.40M | 117.49M | 87.37M | 66.52M | 42.44M | 40.15M | 15.01M | 19.05M | 26.11M | 27.97M | 55.36M | 27.57M | 27.56M | 10.74M | 36.45M | 40.48M | 31.16M | 8.79M |
| Interest Income | 0.00 | 11.08M | 174.00K | 1.70M | 9.92M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.85M | 0.00 | 500.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 607.00K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 81.69M | 26.45M | 40.47M | 29.56M | 27.71M | 25.47M | 5.93M | 3.50M | 2.89M | 2.42M | 2.41M | 763.00K | 10.00K | 109.00K | 781.00K | 1.26M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 10.58M | 24.27M | 27.85M | 20.08M | 10.18M | 4.83M | 2.90M | 2.44M | 1.98M | 1.07M | 680.00K | 561.00K | 343.00K | 54.00K | 707.00K | 1.04M | 406.00K | 3.37M | 12.90M | 34.00K | 96.00K | 346.00K | 1.54M | 789.00K | 86.57K |
| EBITDA | -660.18M | -429.44M | -375.09M | -250.37M | -215.67M | -293.78M | -184.10M | -170.24M | -115.28M | -86.09M | -54.20M | -40.05M | -59.31M | -6.19M | 120.32M | -13.37M | -18.87M | -49.07M | -13.79M | -27.17M | -10.49M | -34.15M | -38.64M | -30.31M | -8.04M |
| EBITDA Ratio | -216.30% | -186.75% | -198.12% | -158.03% | -169.11% | -3,106.12% | 0.00% | 0.00% | 0.00% | -758.47% | -472.77% | 0.00% | -801.13% | -116.14% | -76.81% | -109.99% | -266.08% | -4,429.97% | -11,096.95% | -19,993.43% | -6,914.00% | -830.03% | -13,055.41% | 33,536.67% | -1,212.93% |
| Operating Income | -709.63M | -478.12M | -367.76M | -265.23M | -235.25M | -307.34M | -188.92M | -173.40M | -117.49M | -87.37M | -55.02M | -42.44M | -61.72M | -8.09M | -8.67M | -14.41M | -20.44M | -54.37M | -27.43M | -27.43M | -10.59M | -37.02M | -40.19M | -81.54M | -8.13M |
| Operating Income Ratio | -232.51% | -194.87% | -195.14% | -161.32% | -172.38% | -3,124.94% | 0.00% | 0.00% | 0.00% | -759.70% | -478.39% | 0.00% | -1,397.31% | -116.92% | -83.62% | -123.18% | -271.47% | -5,486.68% | -20,941.98% | -20,018.25% | -7,057.33% | -1,893.81% | -13,576.35% | -135,891.67% | -1,225.98% |
| Total Other Income/Expenses | -37.39M | -2.03M | -61.32M | -27.46M | -18.32M | -16.74M | -4.00M | -2.78M | -2.66M | -2.22M | -2.28M | -1.14M | -23.94M | 1.74M | 127.50M | -1.26M | 477.00K | -1.77M | -13.50M | 222.00K | 288.00K | 607.00K | 3.02M | 1.87M | 0.00 |
| Income Before Tax | -747.01M | -480.15M | -436.41M | -292.69M | -253.56M | -324.08M | -192.92M | -176.18M | -120.15M | -89.58M | -57.29M | -41.37M | -59.66M | -6.36M | 118.83M | -15.67M | -19.96M | -56.14M | -40.93M | -36.42M | -10.30M | -36.42M | -37.17M | -79.66M | 0.00 |
| Income Before Tax Ratio | -244.76% | -195.69% | -231.57% | -178.02% | -185.80% | -3,295.13% | 0.00% | 0.00% | 0.00% | -778.97% | -498.21% | 0.00% | -1,350.78% | -91.84% | 1,145.54% | -133.92% | -265.13% | -5,664.88% | -31,243.51% | -26,581.75% | -6,865.33% | -1,862.76% | -12,557.09% | -132,770.00% | 0.00% |
| Income Tax Expense | 2.56M | 1.38M | -1.76M | 1.40M | 777.00K | 201.00K | -272.00K | 98.00K | -1.97M | -10.42M | -1.22M | 763.00K | 9.18M | 78.00K | 477.00K | 1.26M | 0.00 | 1.77M | 0.00 | -9.21M | -288.00K | 1.93M | -74.34M | 200.00K | -337.57K |
| Net Income | -749.57M | -481.53M | -434.65M | -294.09M | -254.34M | -324.28M | -192.65M | -176.27M | -118.18M | -79.16M | -56.07M | -41.37M | -59.66M | -6.43M | 118.35M | -15.67M | -19.96M | -56.14M | -40.93M | -27.20M | -10.30M | -36.42M | -37.17M | -79.86M | -7.79M |
| Net Income Ratio | -245.59% | -196.26% | -230.63% | -178.87% | -186.37% | -3,297.17% | 0.00% | 0.00% | 0.00% | -688.34% | -487.59% | 0.00% | -1,350.78% | -92.96% | 1,140.94% | -133.92% | -265.13% | -5,664.88% | -31,243.51% | -19,856.20% | -6,865.33% | -1,862.76% | -12,557.09% | -133,103.33% | -1,175.08% |
| EPS | -5.34 | -3.91 | -3.88 | -3.01 | -3.01 | -4.22 | -2.89 | -2.85 | -2.02 | -1.84 | -1.60 | -1.56 | -2.56 | -0.49 | 9.30 | -1.28 | -1.74 | -5.89 | -8.40 | -6.95 | -2.89 | -11.01 | -11.31 | -43.60 | -24.70 |
| EPS Diluted | -5.34 | -3.91 | -3.88 | -3.01 | -3.01 | -4.22 | -2.89 | -2.85 | -2.02 | -1.84 | -1.60 | -1.56 | -2.56 | -0.49 | 9.30 | -1.28 | -1.74 | -5.89 | -8.40 | -6.95 | -2.89 | -11.01 | -11.31 | -43.60 | -24.70 |
| Weighted Avg Shares Out | 140.43M | 123.04M | 112.11M | 97.61M | 84.56M | 76.84M | 66.58M | 61.85M | 58.51M | 43.02M | 34.98M | 26.52M | 23.35M | 13.25M | 12.71M | 12.21M | 11.47M | 9.53M | 4.87M | 3.92M | 3.56M | 3.31M | 3.29M | 1.83M | 315.50K |
| Weighted Avg Shares Out (Dil) | 140.43M | 123.04M | 112.11M | 97.61M | 84.56M | 76.89M | 66.58M | 61.89M | 58.63M | 43.10M | 34.98M | 26.55M | 23.35M | 13.25M | 12.73M | 12.21M | 11.47M | 9.53M | 4.87M | 3.92M | 3.56M | 3.31M | 3.29M | 1.83M | 315.50K |
Insmed (INSM) Expected to Beat Earnings Estimates: Should You Buy?
Insmed (INSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Insmed to Host First-Quarter 2024 Financial Results Conference Call on Thursday, May 9, 2024
BRIDGEWATER, N.J. , April 25, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its first-quarter 2024 financial results...
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BRIDGEWATER, N.J. , April 5, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to seven new...
Insmed to Present New Data from Across its Respiratory Portfolio at the American Thoracic Society 2024 International Conference
—Additional Data from ARISE Study Evaluating the Impact of ARIKAYCE on Microbiologic Outcomes in Patients with Newly Diagnosed or Recurrent MAC Lung Disease to be Presented as Late-Breaker— —Data to be Presented from ARISE Examining Change in Patient-Reported Respiratory Symptoms—...
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BRIDGEWATER, N.J. , March 5, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 24 new...
Insmed To Present at Three March Conferences
BRIDGEWATER, N.J. , Feb. 29, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the following investor conferences:...
Insmed Incorporated (INSM) Q4 2023 Earnings Call Transcript
Insmed Incorporated (INSM) Q4 2023 Earnings Call Transcript
Insmed (INSM) Reports Q4 Loss, Misses Revenue Estimates
Insmed (INSM) came out with a quarterly loss of $1.28 per share versus the Zacks Consensus Estimate of a loss of $1.13. This compares to loss of $1.20 per share a year ago.
Insmed Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Business Update
—Topline Data from the Phase 3 ASPEN Trial of Brensocatib in Adult Patients with Bronchiectasis Remain on Track to Read Out in the Latter Part of Second-Quarter 2024— —Enrollment in the Phase 2 Study of TPIP in Patients with PH-ILD...
Insmed (INSM) Expected to Beat Earnings Estimates: Should You Buy?
Insmed (INSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Source: https://incomestatements.info
Category: Stock Reports